JP2023052069A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023052069A5 JP2023052069A5 JP2022207230A JP2022207230A JP2023052069A5 JP 2023052069 A5 JP2023052069 A5 JP 2023052069A5 JP 2022207230 A JP2022207230 A JP 2022207230A JP 2022207230 A JP2022207230 A JP 2022207230A JP 2023052069 A5 JP2023052069 A5 JP 2023052069A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- cyano
- alkoxy
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 45
- 229910052739 hydrogen Inorganic materials 0.000 claims 42
- 239000001257 hydrogen Substances 0.000 claims 42
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 38
- 125000003545 alkoxy group Chemical group 0.000 claims 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims 25
- -1 bromo, hydroxy Chemical group 0.000 claims 22
- 125000004438 haloalkoxy group Chemical group 0.000 claims 20
- 125000001188 haloalkyl group Chemical group 0.000 claims 20
- 125000001153 fluoro group Chemical group F* 0.000 claims 19
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1708502.8 | 2017-05-26 | ||
| GBGB1708502.8A GB201708502D0 (en) | 2017-05-26 | 2017-05-26 | Inhibitor compounds |
| GBGB1806130.9A GB201806130D0 (en) | 2018-04-13 | 2018-04-13 | Inhibitor compounds |
| GB1806130.9 | 2018-04-13 | ||
| PCT/GB2018/051447 WO2018215801A1 (en) | 2017-05-26 | 2018-05-25 | Benzimidazolone derived inhibitors of bcl6 |
| JP2019565443A JP7202315B2 (ja) | 2017-05-26 | 2018-05-25 | ベンズイミダゾロン由来のｂｃｌ６阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565443A Division JP7202315B2 (ja) | 2017-05-26 | 2018-05-25 | ベンズイミダゾロン由来のｂｃｌ６阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023052069A JP2023052069A (ja) | 2023-04-11 |
| JP2023052069A5 true JP2023052069A5 (enExample) | 2023-11-07 |
| JP7534379B2 JP7534379B2 (ja) | 2024-08-14 |
Family
ID=62563184
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565443A Active JP7202315B2 (ja) | 2017-05-26 | 2018-05-25 | ベンズイミダゾロン由来のｂｃｌ６阻害剤 |
| JP2022207230A Active JP7534379B2 (ja) | 2017-05-26 | 2022-12-23 | ベンズイミダゾロン由来のｂｃｌ６阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565443A Active JP7202315B2 (ja) | 2017-05-26 | 2018-05-25 | ベンズイミダゾロン由来のｂｃｌ６阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12110286B2 (enExample) |
| EP (2) | EP3630291B9 (enExample) |
| JP (2) | JP7202315B2 (enExample) |
| KR (2) | KR102628675B1 (enExample) |
| CN (2) | CN111163839B (enExample) |
| AU (2) | AU2018274723B2 (enExample) |
| CA (1) | CA3065005A1 (enExample) |
| ES (1) | ES2975690T3 (enExample) |
| IL (2) | IL302300B1 (enExample) |
| MX (1) | MX2023005636A (enExample) |
| WO (1) | WO2018215801A1 (enExample) |
| ZA (1) | ZA202405646B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3630291B9 (en) * | 2017-05-26 | 2024-05-29 | Cancer Research Technology Limited | Benzimidazolone derived inhibitors of bcl6 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| EP3765516A2 (en) * | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| IL296734B2 (en) | 2018-04-13 | 2025-06-01 | The Institute Of Cancer Res Royal Cancer Hospital | Bcl6 inhibitors |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| GB201819126D0 (en) * | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR102922115B1 (ko) | 2019-04-09 | 2026-02-04 | 누릭스 테라퓨틱스 인코포레이티드 | Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도 |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| GB201909573D0 (en) | 2019-07-03 | 2019-08-14 | Cancer Research Tech Ltd | Modulation of T cell cytotoxicity and related therapy |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| US12653809B2 (en) | 2019-07-30 | 2026-06-16 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| MX2022004526A (es) | 2019-10-17 | 2022-07-21 | Arvinas Operations Inc | Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6. |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| CA3192868A1 (en) * | 2020-09-24 | 2022-03-31 | Auckland Uniservices Limited | Novel aminopyridines and their use in treating cancer |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
| CN118388454A (zh) | 2021-04-16 | 2024-07-26 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその合成 |
| EP4463166A4 (en) * | 2022-01-14 | 2025-12-31 | Kymera Therapeutics Inc | IRAQ4 DEGRADATION AGENTS AND THEIR USES |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| CA3251059A1 (en) | 2022-05-02 | 2023-11-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions, systems and methods for modulating a target gene |
| WO2023240038A1 (en) | 2022-06-06 | 2023-12-14 | Treeline Biosciences, Inc. | Tricyclic quinolone bcl6 bifunctional degraders |
| KR20250023483A (ko) | 2022-06-13 | 2025-02-18 | 트리라인 바이오사이언시스, 인크. | 퀴놀론 bcl6 이작용성 분해제 |
| AU2023295387A1 (en) | 2022-06-13 | 2025-01-09 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
| JP2025534769A (ja) * | 2022-10-17 | 2025-10-17 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｂｃｌ６のアルキルアミン含有小分子分解剤 |
| EP4626884A1 (en) | 2022-11-30 | 2025-10-08 | Blueprint Medicines Corporation | N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria |
| WO2024191788A1 (en) * | 2023-03-10 | 2024-09-19 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0259572A (ja) * | 1988-08-23 | 1990-02-28 | Mitsubishi Kasei Corp | ベンズイミダゾロン誘導体又はその塩類 |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| WO2008066887A2 (en) * | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
| WO2009063240A1 (en) | 2007-11-16 | 2009-05-22 | Arrow Therapeutics Limited | 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
| WO2009097578A1 (en) | 2008-02-01 | 2009-08-06 | Takeda Pharmaceutical Company Limited | Oxim derivatives as hsp90 inhibitors |
| PL2389372T3 (pl) * | 2009-01-23 | 2016-02-29 | Rigel Pharmaceuticals Inc | Kompozycje i sposoby hamowania szlaku JAK |
| CN102791131A (zh) | 2010-01-13 | 2012-11-21 | 葛兰素史密斯克莱有限责任公司 | 化合物和方法 |
| ES2698847T3 (es) * | 2011-07-07 | 2019-02-06 | Merck Patent Gmbh | Azaheterociclos sustituidos para el tratamiento del cáncer |
| CN102503896A (zh) * | 2011-10-25 | 2012-06-20 | 西北农林科技大学 | 甲基丙烯酰基苯并咪唑（硫）酮衍生物及其作为抗菌药物的用途 |
| CN104922116B (zh) * | 2014-03-23 | 2020-08-11 | 上海诗丹德生物技术有限公司 | 甲基丙烯酰基苯并咪唑酮衍生物的用途 |
| CN105017159B (zh) | 2014-04-28 | 2019-05-17 | 四川大学 | 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途 |
| ES2914099T3 (es) * | 2014-08-25 | 2022-06-07 | Salk Inst For Biological Studi | Inhibidores novedosos de ULK1 y métodos de uso de los mismos |
| US20160060260A1 (en) * | 2014-08-29 | 2016-03-03 | Board Of Regents, The University Of Texas System | Bromodomain inhibitors for treating disease |
| WO2017007658A1 (en) * | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | A combination for immune mediated cancer treatment |
| JP6999688B2 (ja) | 2016-12-13 | 2022-02-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｃｌ６阻害剤としての新規の６－アミノキノリノン化合物および誘導体 |
| EP3630749B9 (en) | 2017-05-26 | 2024-05-29 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
| EP3630291B9 (en) | 2017-05-26 | 2024-05-29 | Cancer Research Technology Limited | Benzimidazolone derived inhibitors of bcl6 |
-
2018
- 2018-05-25 EP EP18730042.1A patent/EP3630291B9/en active Active
- 2018-05-25 IL IL302300A patent/IL302300B1/en unknown
- 2018-05-25 EP EP24150697.1A patent/EP4374858A3/en active Pending
- 2018-05-25 AU AU2018274723A patent/AU2018274723B2/en active Active
- 2018-05-25 CA CA3065005A patent/CA3065005A1/en active Pending
- 2018-05-25 JP JP2019565443A patent/JP7202315B2/ja active Active
- 2018-05-25 ES ES18730042T patent/ES2975690T3/es active Active
- 2018-05-25 KR KR1020197038091A patent/KR102628675B1/ko active Active
- 2018-05-25 WO PCT/GB2018/051447 patent/WO2018215801A1/en not_active Ceased
- 2018-05-25 US US16/616,901 patent/US12110286B2/en active Active
- 2018-05-25 KR KR1020247002176A patent/KR102828518B1/ko active Active
- 2018-05-25 CN CN201880047061.XA patent/CN111163839B/zh active Active
- 2018-05-25 IL IL270869A patent/IL270869B2/en unknown
- 2018-05-25 CN CN202410618580.4A patent/CN118561812A/zh active Pending
-
2019
- 2019-11-25 MX MX2023005636A patent/MX2023005636A/es unknown
-
2022
- 2022-12-23 JP JP2022207230A patent/JP7534379B2/ja active Active
-
2024
- 2024-04-17 AU AU2024202525A patent/AU2024202525B2/en active Active
- 2024-07-19 ZA ZA2024/05646A patent/ZA202405646B/en unknown
- 2024-08-08 US US18/798,355 patent/US20240417388A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2497807C2 (ru) | Карбазольные соединения и терапевтические применения соединений | |
| JP2005538100A5 (enExample) | ||
| JP2020510091A5 (enExample) | ||
| JP2023521351A5 (enExample) | ||
| MY144048A (en) | Chemical compound | |
| JP2015537017A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| TW200604186A (en) | Compounds | |
| TW200602028A (en) | Compounds | |
| CA2668997A1 (en) | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors | |
| RU2019130519A (ru) | 4-пиридоновое соединение или его соль, фармацевтическая композиция и содержащий их состав | |
| JP2008530099A5 (enExample) | ||
| JP2018529739A5 (enExample) | ||
| JP2007529534A5 (enExample) | ||
| RU2009101298A (ru) | Гетероциклические соединения в качестве усилителей подслащивающего вещества | |
| JP2006516143A5 (enExample) | ||
| IL276575B1 (en) | Inhibitors of btk and mutants thereof | |
| ZA200508158B (en) | Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | |
| JP2005505618A5 (enExample) | ||
| JP2015529217A5 (enExample) | ||
| JP2020514315A5 (enExample) | ||
| JP2013540712A5 (enExample) | ||
| JP2005518357A5 (enExample) | ||
| JP2022533939A5 (enExample) | ||
| JP2005525392A5 (enExample) |